Shares of Alkermes (ALKS -0.4%) fail to get a spark from todays buying, largely due to Credit Suisse initiating the stock with a tepid Neutral rating and lackluster $24 price target. The firm says ALKS has an enticing long-term story, but its recent run (the stock is already +21% YTD versus +7% for its peers) leaves the broker looking for a better entry point. Additionally, a potentially negative readout for its depression drug candidate ALKS 5461 poses near-term risks.
Are you Bullish or Bearish on ?
Sentiment on ()
Thanks for sharing your thoughts.